Premium
Inhibition of P ‐glycoprotein by psychotherapeutic drugs in a canine cell model
Author(s) -
Schrickx J. A.,
FinkGremmels J.
Publication year - 2014
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/jvp.12111
Subject(s) - clomipramine , fluoxetine , pharmacology , p glycoprotein , antidepressant , tricyclic , reuptake inhibitor , drug , serotonin , anxiety , transporter , medicine , chemistry , multiple drug resistance , psychiatry , biochemistry , receptor , gene , antibiotics
Drug–drug interactions related to long‐term therapies are of increasing concern. Psychotherapeutic drugs, licensed for the use in dogs for the management of separation anxiety and other behavioural disorders, are examples of drugs used in long‐term therapies. In an in vitro system with canine P‐glycoprotein (P‐gp) expressing cell lines, three psychotherapeutic drugs with a different mode of action were tested for their ability to inhibit the canine multidrug transporter P‐gp. At 10 μ m , the selective serotonin reuptake inhibitor fluoxetine and the tricyclic antidepressant clomipramine inhibited P‐gp for 41% and 59%, respectively. In contrast, selegeline did not inhibit the function of the canine P‐gp.